Skip to main content

Table 2 Analyses of HMA combinations with Doxo on BCP-ALL cells

From: Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

  Drug combination effect
AZA + Doxo AZA + Doxo (24 h) Doxo + AZA (24 h) DEC + Doxo DEC + Doxo (24 h) Doxo + DEC (24 h)
SEM Metabolism − 0.071 − 0.230 0.006 − 0.046 − 0.117 − 0.021
Proliferation − 0.002 − 0.192 0.015 − 0.014 − 0.094 − 0.042
RS4;11 Metabolism − 0.009 − 0.118 0.086 − 0.007 − 0.071 0.044
Proliferation − 0.022 − 0.227 0.016 − 0.028 − 0.301 0.011
  1. Drug combination effect: difference between the observed and the expected inhibition (E) of combined treatment. E is calculated as follows: E = (A + B) − (A*B); A is inhibition effect of drug A; B inhibition effect of drug B values > 0: synergistic, values < 0: antagonistic